Crossmark

Epigenetic therapy in immune-oncology

Crossref DOI link: https://doi.org/10.1038/s41568-019-0109-9

Published Online: 2019-02-05

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jones, Peter A. https://orcid.org/0000-0001-8309-4767
Ohtani, Hitoshi

Chakravarthy, Ankur

De Carvalho, Daniel D. https://orcid.org/0000-0002-8572-5259
License Information

Text and Data Mining valid from 2019-02-05
More Information

Article History

First Online: 5 February 2019

Competing interests

: P.A.J. is a consultant for Zymo Inc. D.D.D.C. receives research funding from Nektar Therapeutics. H.O. and A.C. declare no competing interests.